申请人:Novartis AG
公开号:EP1878733A1
公开(公告)日:2008-01-16
Compounds of formula I
in free or salt or solvate form, where T1, T2, K, Ra and Rb have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
公式I中的化合物以自由形式、盐或溶剂形式存在,其中T1、T2、K、Ra和Rb的含义如规范中所示,可用于治疗由ALK-5和/或ALK-4受体介导的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的过程。